Intra-Cellular Therapies Stock Forecast, Price & News

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" Intra-Cellular Therapies stock.
View analyst ratings for Intra-Cellular Therapies or view top-rated stocks.

8 equities research analysts have issued 12-month price objectives for Intra-Cellular Therapies' stock. Their ITCI stock forecasts range from $40.00 to $75.00. On average, they predict Intra-Cellular Therapies' share price to reach $62.25 in the next twelve months. This suggests a possible upside of 12.7% from the stock's current price.
View analysts' price targets for Intra-Cellular Therapies or view top-rated stocks among Wall Street analysts.

Intra-Cellular Therapies' stock was trading at $52.34 at the beginning of 2022. Since then, ITCI stock has increased by 5.5% and is now trading at $55.23.
View the best growth stocks for 2022 here.

Intra-Cellular Therapies saw a decrease in short interest in the month of May. As of May 31st, there was short interest totaling 3,120,000 shares, a decrease of 18.8% from the May 15th total of 3,840,000 shares. Based on an average daily volume of 874,100 shares, the short-interest ratio is currently 3.6 days.
View Intra-Cellular Therapies' Short Interest.

Intra-Cellular Therapies is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Intra-Cellular Therapies.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.93) by $0.15. The biopharmaceutical company earned $35 million during the quarter, compared to analysts' expectations of $33.52 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 53.93% and a negative net margin of 294.89%. The company's revenue for the quarter was up 120.1% on a year-over-year basis. During the same period in the prior year, the company earned ($0.65) EPS.
View Intra-Cellular Therapies' earnings history.

Some companies that are related to Intra-Cellular Therapies include Genmab A/S (GMAB), Genmab A/S (GNMSF), Catalent (CTLT), Horizon Therapeutics Public (HZNP), Alnylam Pharmaceuticals (ALNY), BeiGene (BGNE), UCB (UCBJF), Shiseido (SSDOY), BioMarin Pharmaceutical (BMRN), Viatris (VTRS), Ono Pharmaceutical (OPHLF), United Therapeutics (UTHR), Biohaven Pharmaceutical (BHVN), Jazz Pharmaceuticals (JAZZ) and Elanco Animal Health (ELAN).
View all of ITCI's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

Intra-Cellular Therapies' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.26%), Wasatch Advisors Inc. (7.93%), BlackRock Inc. (6.86%), Wellington Management Group LLP (4.31%), Bellevue Group AG (3.64%) and Lord Abbett & CO. LLC (2.10%). Company insiders that own Intra-Cellular Therapies stock include Andrew Satlin, Christopher D Alafi, Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Lawrence J Hineline, Mark Neumann, Michael Halstead, Rory B Riggs, Sharon Mates and Suresh K Durgam.
View institutional ownership trends for Intra-Cellular Therapies.

ITCI stock was sold by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., TimesSquare Capital Management LLC, Bellevue Group AG, Lord Abbett & CO. LLC, DCF Advisers LLC, Rhenman & Partners Asset Management AB, Clearbridge Investments LLC, and Nicholas Investment Partners LP. Company insiders that have sold Intra-Cellular Therapies company stock in the last two years include Christopher D Alafi, Joel S Marcus, Lawrence J Hineline, Mark Neumann, Michael Halstead, Rory B Riggs, Sharon Mates, and Suresh K Durgam.
View insider buying and selling activity for Intra-Cellular Therapies or view top insider-selling stocks.

ITCI stock was purchased by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, Victory Capital Management Inc., Vanguard Group Inc., BlackRock Inc., Hood River Capital Management LLC, Invesco Ltd., Polar Capital Holdings Plc, and Suvretta Capital Management LLC.
View insider buying and selling activity for Intra-Cellular Therapies or or view top insider-buying stocks.

Shares of ITCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ITCI stock can currently be purchased for approximately $55.23.

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.21 billion and generates $83.80 million in revenue each year. The biopharmaceutical company earns $-284.13 million in net income (profit) each year or ($3.630010) on an earnings per share basis.

Intra-Cellular Therapies employs 512 workers across the globe.

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for Intra-Cellular Therapies is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at [email protected], or via fax at 646-440-9334.